Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LAFAREX is an insect growth regulator (IGR) developed by IOCB TECH, containing the active ingredient methoprene. It functions as a juvenoid, or juvenile hormone analog, which mimics the natural hormones responsible for regulating insect development and metamorphosis. By binding as an agonist to the insect juvenile hormone receptor, LAFAREX disrupts the normal life cycle of Pharaoh's ants (*Monomorium pharaonis*), preventing larvae from reaching adulthood and inducing sterility in the queen. This targeted approach leads to the eventual eradication of the entire ant colony. LAFAREX is an approved product for the management of indoor ant infestations.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on methoprene.